Recruiting Leukemia Studies in Hangzhou
Volrustomig Priming Regimens Exploratory Phase II Platform Study
Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with spe...
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs. Full extrapolation of the efficacy of asciminib fro...
About Leukemia Clinical Trials in Hangzhou
Leukemia is a group of blood cancers that develop in the bone marrow and result in abnormal white blood cells. Types include acute myeloid (AML), acute lymphoblastic (ALL), chronic myeloid (CML), and chronic lymphocytic (CLL). Treatment varies by type and may include chemotherapy, targeted therapy, and stem cell transplant.
There are currently 2 leukemia clinical trials recruiting participants in Hangzhou, ZHEJIANG. These studies are seeking a combined 224 participants. Research is being sponsored by AstraZeneca, Novartis Pharmaceuticals. Clinical trial participation is free and participants receive study-related medical care at no cost.
Leukemia Clinical Trials in Hangzhou — FAQ
Are there leukemia clinical trials in Hangzhou?
Yes, there are 2 leukemia clinical trials currently recruiting in Hangzhou, ZHEJIANG. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Hangzhou?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Hangzhou research site will contact you about next steps.
Are clinical trials in Hangzhou free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Hangzhou studies also compensate for your time and travel.
What leukemia treatments are being tested?
The 2 active trials in Hangzhou are testing new therapies including novel drugs, biologics, and treatment approaches for leukemia.
Data updated March 2, 2026 from ClinicalTrials.gov